Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omega-3 Fatty Acids in Sarcopenia
NCT02103842Phase 1Completed
- Sponsor
- Mayo Clinic
- Start
- Mar 2014
- Primary completion
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of omega-3 fatty acid in Sarcopenia, sponsored by Mayo Clinic. Primary endpoints: Change in Muscle protein synthesis at 4 months and Change in Muscle mitochondrial function at 4 months. Started Mar 2014; status: completed.
02
Drugs
omega-3 fatty acid
03
Conditions
Sarcopenia
Beyond the preview
Go deeper on NCT02103842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02103842.